Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease

Blood

Volumn 121, Issue 12, 2013, Pages 2340-2346

  Inamoto, Yoshihiro ^a   Storer, Barry E ^a,b   Lee, Stephanie J ^a,b   Carpenter, Paul A ^a,b   Sandmaier, Brenda M ^a,b   Flowers, Mary E D ^a,b   Martin, Paul J ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLATE MOFETIL; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; FAILURE FREE SURVIVAL; FEMALE; HIGH RISK POPULATION; HUMAN; HYPERBILIRUBINEMIA; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MYELOID LEUKEMIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; RISK ASSESSMENT; SYSTEMIC THERAPY; THROMBOCYTOPENIA; TREATMENT FAILURE; ADJUVANT CHEMOTHERAPY; CHRONIC DISEASE; DISEASE FREE SURVIVAL; EVALUATION; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INFANT; INTRAVENOUS ADMINISTRATION; MIDDLE AGED; PRESCHOOL CHILD; RETROSPECTIVE STUDY;

ADMINISTRATION, INTRAVENOUS; ADOLESCENT; ADULT; AGED; CHEMOTHERAPY, ADJUVANT; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; MALE; MIDDLE AGED; PREDNISONE; RETROSPECTIVE STUDIES; TREATMENT FAILURE; YOUNG ADULT;

MLCS; MLOWN;

EID: 84876301668     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-11-465583     Document Type: Article

References (34)

1. Flowers ME, Storer B, Carpenter P, et al. Treatment change as a predictor of outcome among patients with classic chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2008;14(12):1380-1384.
2. Wolff D, Schleuning M, von Harsdorf S, et al. Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2011;17(1):1-17.
3. Lee SJ, Vogelsang G, Gilman A, et al. A survey of diagnosis, management, and grading of chronic GVHD. Biol Blood Marrow Transplant. 2002;8(1): 32-39.
4. Lee SJ, Joffe S, Artz AS, et al. Individual physician practice variation in hematopoietic cell transplantation. J Clin Oncol. 2008;26(13): 2162-2170.
5. Martin PJ, Weisdorf D, Przepiorka D, et al. Design of Clinical Trials Working Group. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report. Biol Blood Marrow Transplant. 2006;12(5):491-505.
6. Martin PJ, Inamoto Y, Carpenter PA, et al. Treatment of chronic graft-versus-host disease: Past, present and future. Korean J Hematol. 2011; 46(3):153-163.
7. Inamoto Y, Flowers ME. Treatment of chronic graft-versus-host disease in 2011. Curr Opin Hematol. 2011;18(6):414-420.
8. Pavletic SZ, Martin P, Lee SJ, et al; Response Criteria Working Group. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant. 2006;12(3):252-266.
9. Martin PJ, Storer BE, Carpenter PA, et al. Comparison of short-term response and long-term outcomes after initial systemic treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2011;17(1):124-132.
10. Palmer JM, Lee SJ, Chai X, et al. Poor agreement between clinician response ratings and calculated response measures in patients with chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2012;18(11):1649-1655.
11. Inamoto Y, Martin PJ, Chai X, et al. Chronic GVHD Consortium; Clinical benefit of response in chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2012;18(10):1517-1524.
12. Kim SJ, Lee JW, Jung CW, et al. Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study. Haematologica. 2010;95(11):1935-1942.
13. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945-956.
14. Chien JW, Duncan S, Williams KM, et al. Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation-an increasingly recognized manifestation of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2010;16(1 Suppl):S106-S114.
15. Martin PJ, Storer BE, Rowley SD, et al. Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. Blood. 2009; 113(21):5074-5082.
16. Martin PJ, Gilman AL. Front Line Treatment of Chronic GVHD. In: Vogelsang G, Pavletic S, eds. Chronic Graft Versus Host Disease: Interdisciplinary Management. New York: Cambridge University Press; 2009:124-133.
17. Vigorito AC, Campregher PV, Storer BE, et al. National Institutes of Health. Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. Blood. 2009;114(3):702-708.
18. Gooley TA, Leisenring W, Crowley J, et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18(6):695-706.
19. Martin PJ, Carpenter PA, Sanders JE, et al. Diagnosis and clinical management of chronic graft-versus-host disease. Int J Hematol. 2004; 79(3):221-228.
20. Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2003;9(4):215-233.
21. Smitten AL, Choi HK, Hochberg MC, et al. The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol. 2008;35(3):387-393.
22. Flowers ME, Apperley JF, van Besien K, et al; A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood. 2008;112(7):2667-2674.
23. Greinix HT, van Besien K, Elmaagacli AH, et al; UVADEX Chronic GVHD Study Group. Progressive improvement in cutaneous and extracutaneous chronic graft-versus-host disease after a 24-week course of extracorporeal photopheresis—results of a crossover randomized study. Biol Blood Marrow Transplant. 2011;17(12):1775-1782.
24. Lee SJ, Klein JP, Barrett AJ, et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood. 2002;100(2):406-414.
25. Cho BS, Min CK, Eom KS, et al. Feasibility of NIH consensus criteria for chronic graft-versus-host disease. Leukemia. 2009;23(1):78-84.
26. Arai S, Jagasia M, Storer B, et al. Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. Blood. 2011;118(15):4242-4249.
27. Khera N, Storer B, Flowers ME, et al. Nonmalignant late effects and compromised functional status in survivors of hematopoietic cell transplantation. J Clin Oncol. 2012;30(1):71-77.
28. Stewart BL, Storer B, Storek J, et al. Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood. 2004;104(12): 3501-3506.
29. Inamoto Y, Flowers ME, Lee SJ, et al. Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation. Blood. 2011;118(2):456-463.
30. Socié G, Schmoor C, Bethge WA, et al; ATG-Fresenius Trial Group. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood. 2011;117(23):6375-6382.
31. Couriel DR, Saliba R, Escalón MP, et al. Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. Br J Haematol. 2005;130(3):409-417.
32. Cutler C, Miklos D, Kim HT, et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood. 2006;108(2):756-762.
33. Jacobsohn DA, Chen AR, Zahurak M, et al. Phase II study of pentostatin in patients with corticosteroid-refractory chronic graft-versus-host disease. J Clin Oncol. 2007;25(27):4255-4261.
34. Chen GL, Arai S, Flowers ME, et al. A phase 1 study of imatinib for corticosteroid-dependent/ refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies. Blood. 2011;118(15):4070-4078.